Transformational Prevention Unit

Obesity is a serious, progressive, and chronic disease with far-reaching consequences – it is associated with >200 complications, including type 2 diabetes and cardiovascular disease.¹ Almost 1 billion people worldwide are currently affected by obesity and that number is predicted to rise to nearly 2 billion by 2035. ²

It has been a decade since members of the World Health Organization set a target to halt the rise of obesity by 2025, but no country is on track to meet it – despite the various efforts put forward.

As leaders within the science of obesity, Novo Nordisk established the Transformational Prevention Unit (TPU) to tackle one of the world’s foremost health challenges and drive change within obesity prevention.

The Transformational Prevention Unit (TPU) is a pioneering scientific and business innovation unit that will deliver science-first, empowering, and scalable commercial solutions that predict and pre-empt obesity and its consequences through innovative partnerships. These solutions intend to push the boundaries of what is possible with drugs, genomics, microbiome, digital health, and behavioral science.

By leveraging our deep knowledge of the science of obesity, the TPU will identify people at high-risk for developing obesity and its consequences and aim to deliver targeted interventions to stop them from developing obesity in the first place. This has the potential to reduce the number of new cases of obesity amongst people at high-risk and prolong the duration of time people live without obesity.

Tackling one of the world’s foremost health challenges will require novel, multi-sector partnerships, especially in the areas of science, technology, and implementation. Are you ready to drive change with us? Fill out the form below to get in touch with the TPU.

Your name *

Please enter your name

Your e-mail *

Must be a valid email address Value must a valid email

{{crossValidationError['Industry type'].crossValidationErrorMessage}}

Your message *

Please add a message

*

Attach a file +

Your attachment is too big. You can attach up to 20MB Following file extensions are allowed .xls,.xlsx,.doc,.docx,.ppt,.pptx,.pdf,.msg,.eml,.jpeg,.png {{crossValidationError['attachment'].crossValidationErrorMessage}}

You may for example attach images, reports or other files which may aid in the understanding and handling of your complaint. When you attach, please be patient on submission of your message.

Privacy disclaimer * *

By submitting this form, I agree to Novo Nordisk privacy and disclaimer information

You must accept Privacy Disclaimer

The TPU is a pioneering unit within Novo Nordisk that has been created with high autonomy to push boundaries and encourage agility and speed. It spans across the Research & Early Development (R&ED) and Commercial organizations and is guided by an internal board.

The TPU is comprised of a global team of interdisciplinary experts ranging from drug R&D, human biology, data science, behavioural psychology, public health, digital technologies, marketing, and communications.

Bridget Lilliehöök, Vice President, Strategy & Operations

Yuen, M., Earle, R., Kadambi, N., Brancale, J., Lui, D., Kahan, S. and Kaplan, L. (2016). A systematic review and evaluation of current evidence reveals 236 obesity-associated disorders [Poster T-P-3166]. Obesity Week 2016, Oct 31–Nov 4 2016, New Orleans.

World Obesity Federation, World Obesity Atlas 2023. https://data.worldobesity.org/publications/?cat=19